ReviewDiscover oncology2025
IgE based therapeutics are an emerging modality in cancer treatment.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeting human diseases using antibodies is a rapidly evolving area of research that could transform healthcare. Currently, various diseases, including cancer, are treated by immunotherapy using the IgG class of antibodies. Recently, efforts have been made to broaden the range of available treatments by utilizing the distinct features of other antibody classes. Notably, the IgE antibody has shown encouraging results in restricting tumor growth with the first therapeutic antibody MOv18 IgE showing promising results in clinical trials, with good tolerance and safety in patients with ovarian carcinoma. However, several challenges remain. This review discusses recent developments in the engineering of the IgE antibody for cancer therapeutics, focusing on improving manufacturability and reducing immunogenicity by modifying IgE glycosylation complexity. Additionally, bispecific formats of IgE are being established to engage multiple targets simultaneously. Building on the recent studies in these areas, the ongoing research on IgE therapeutics has provided potential opportunities for clinical development and as a therapy in the future. These outcomes and advancements, along with a better clinical safety profile, may increase the treatment options for cancer patients in the future together with existing and approved IgG therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.